store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Taurodeoxycholic acid (Taurodeoxychloic acid) 是脱氧胆酸的胆汁酸牛磺酸共轭物,是一种人体代谢物,可稳定线粒体膜,减少自由基形成。Taurodeoxycholic acid 通过阻断钙介导的凋亡通路以及 Caspase-12 激活来抑制凋亡 (apoptosis)。Taurodeoxycholic acid具有神经保护活性,可用于研究 3-硝基丙酸诱导或稳定遗传的亨廷顿舞蹈病 (HD) 。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 398 | 现货 | ||
5 mg | ¥ 1,090 | 现货 | ||
10 mg | ¥ 1,430 | 现货 | ||
25 mg | ¥ 2,820 | 现货 | ||
50 mg | ¥ 4,250 | 现货 | ||
100 mg | ¥ 5,930 | 现货 | ||
500 mg | ¥ 12,300 | 现货 |
产品描述 | Taurodeoxycholic acid (Taurodeoxychloic acid) is a bile acid taurine conjugate of deoxycholic acid, a human metabolite that stabilizes mitochondrial membranes and reduces the formation of free radicals.Taurodeoxycholic acid inhibits apoptosis by blocking calcium-mediated apoptotic pathways and by activation of caspase-12. Taurodeoxycholic acid has neuroprotective activity and has been used to study 3-nitropropionic acid-induced or stabilized hereditary Huntington's chorea (HD). |
体外活性 |
Taurodeoxycholic acid (50, 100 μM; 4 h) increases oligonuclear DNA cleavage and nuclear apoptosis in primary human hepatocytes.[1] Taurodeoxycholic acid (400 μM; 18-24 h) increases DNA fragmentation and PARP cleavage and induces apoptosis in human liver-derived Huh7 cells.[2] |
体内活性 |
Taurodeoxycholic acid (50 mg/kg; i.p.; once daily for 34 days; Huntington's disease model in mice) prevents neuropathology and associated behavioral deficits in a rat model of Huntington's disease (HD).[3] Taurodeoxycholic acid (500 mg/kg; subcutaneous injection; every 3 days for 7 weeks; Huntington's disease model in mice) resulted in a significant reduction in striatal neuropathology in R6/2 transgenic HD mice.[4] |
别名 | Taurodeoxychloic acid |
分子量 | 499.7 |
分子式 | C26H45NO6S |
CAS No. | 516-50-7 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL, (100 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0012 mL | 10.006 mL | 20.012 mL | 50.03 mL |
5 mM | 0.4002 mL | 2.0012 mL | 4.0024 mL | 10.006 mL | |
10 mM | 0.2001 mL | 1.0006 mL | 2.0012 mL | 5.003 mL | |
20 mM | 0.1001 mL | 0.5003 mL | 1.0006 mL | 2.5015 mL | |
50 mM | 0.04 mL | 0.2001 mL | 0.4002 mL | 1.0006 mL | |
100 mM | 0.02 mL | 0.1001 mL | 0.2001 mL | 0.5003 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Taurodeoxycholic acid 516-50-7 Apoptosis Membrane transporter/Ion channel Metabolism Proteases/Proteasome Calcium Channel Caspase Taurodeoxychloic acid Inhibitor inhibitor inhibit